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Treatment failure of solid cancers, represented by the development of drug resistance
in the primary tumor or later outgrowth of drug resistant metastases, is the major
cause of death for cancer patients. It represents an urgent clinical need for predictive
biomarkers which indicate the success or failure of standard treatment regimens.
Besides treatment prediction, interfering with cellular processes associated with drug
resistance might improve treatment response by applying combination therapies.
Metastasis-associated in colon cancer (MACC) 1 was identified in our group as a
prognostic biomarker in human colorectal cancer, and has been established as key
player, prognostic, and predictive biomarker for tumor progression and metastasis in
a variety of solid cancers. Besides increased cell proliferation and motility, subsequently
contributing to growth and metastatic spread of the primary tumor, MACC1 has also
been shown to dysregulate apoptosis and is contributing to treatment resistance. Here
we report the MACC1 dependent treatment resistance of colorectal cancer (CRC) cells to
standard therapeutics like doxorubicin by upregulating ATP-binding cassette subfamily
B member 1 (ABCB1) protein. Overexpression of MACC1 in CRC cells increased
both its presence on the ABCB1 promoter and its transcriptional activity, resulting in
elevated ABCB1 expression and thus treatment resistance to standard therapeutics. In
contrast, depleting MACC1 increased intracellular drug concentrations, leading to better
treatment response. We already identified the first MACC1 transcriptional inhibitors,
such as lovastatin, by high-throughput screening of clinically approved small molecule
drugs. These compounds inhibited cell motility in vitro but also restricted metastasis
development in xenograft mouse models by reducing MACC1 expression. Here we
report, that treating high MACC1 expressing CRC cells with a combination of statins
and standard therapeutics increased the rate of cytotoxicity and resulted in higher
treatment response.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer
type worldwide and second in cancer-related deaths in Europe.
About 1.8 million individuals are diagnosed with CRC annually
worldwide and the disease-related mortality corresponds to
about 50% (1, 2). Tumor stages at time of diagnosis negatively
correlate with patient survival (3) as cell dissemination has often
taken place in advanced stages of the disease, which critically
limits the curation by surgery alone. In addition, resistance
of the primary tumor to standard and targeted chemotherapy
or the outgrowth of distant metastases are the main causes
for treatment failure, defining a strong demand for alternative
treatment strategies to overcome these obstacles.
Cancer cells can gain resistance to cytotoxic therapeutics
by a variety of cellular mechanisms, which often lead to a
resistant phenotype for multiple drugs. One general mechanism
of drug resistance is the elevated expression of members
of the ATP-binding cassette (ABC) transporter superfamily,
comprehensively reviewed in Gottesman et al. (4). Among others,
drug resistance in cancer cells is often caused by increased
expression of the ABC subfamily B member 1 (ABCB1), which
is also referred to as multi-drug resistance protein (MDR) 1
and permeability glycoprotein (P-gp). ABCB1mediates increased
efflux of a broad range of natural or synthetic compounds, e.g.,
anthracyclines or vinca alkaloids (5). Overcoming the multi-drug
resistant phenotype by targeting ABCB1 in cancer cells at the
functional or transcriptional level is a constant topic of anti-
cancer research (6, 7), which will allow to re-use anthracyclines,
like doxorubicin, as highly effective anti-cancer drugs in CRC
(8, 9).
An emerging factor for the regulation of therapy resistance
is the gene metastasis-associated in colon cancer (MACC) 1.
MACC1 has been identified as a prognostic and predictive
biomarker for many solid cancer types besides CRC (10, 11). Its
expression in the primary tumors drives metastasis formation,
allowing the stratification of high-risk patients even at early stages
(10). Moreover, besides inducing metastasis formation, MACC1
expression is also associated with increased resistance to standard
and targeted therapeutics in several cancer types, including
CRC (12–15). After first describing the promoter region and
expression regulation of MACC1 in CRC (16) we identified
mevastatin as transcriptional inhibitor of MACC1 expression in
a high-throughput drug screening, and confirmed the same effect
for the FDA-approved lovastatin in vitro, as well as in xenograft
mouse models for metastasis formation (17).
With this study, we want to explore the possibility of restoring
the susceptibility of multi-drug resistant CRC cells to common,
but efficient anti-cancer drugs like doxorubicin, by combination
therapy and repositioning of drugs that target the expression
of MACC1.
MATERIALS AND METHODS
Cell Lines and Growth Conditions
Human CRC cell lines SW480, SW620, and HCT15, all
originally from the American Type Culture Collection, were
grown in DMEM supplemented with 10% fetal bovine serum
(both Thermo Fisher Scientific). The generation of stable
SW480 cell lines, with or without ectopic MACC1 expression
(SW480/MACC1 and SW480/ev, respectively), was previously
described (10). The genetic knock-out of MACC1 in the SW620
cell line was performed with the CRISPR/Cas technology,
resulting in a guide RNA-mediated shift in the reading frame
of MACC1 exon 4 (gRNA: 5′-CAC ATC AAG TTC ATC
ACC GAG G-3′; SW620/ko-MACC1) and the control cell line
without the transfection of guide RNA (SW620/ctrl). Alterations
in the MACC1-coding region of single-cell sorted clones were
confirmed by Sanger sequencing. All cells were maintained at
37◦C in a humidified incubator with 5% CO2. All cells tested
negative for mycoplasma, verified regularly using the MycoAlert
Mycoplasma detection kit (Lonza). Authentication of the cell
lines was performed by short tandem repeat (STR) genotyping
at the Leibniz-Institute DSMZ (Braunschweig, Germany). STR
genotypes were consistent with published genotypes for these
cell lines.
RNA Extraction and qRT-PCR
300,000 cells were grown in 6-well plates and total RNA was
isolated using the Universal RNA Purification Kit (Roboklon,
Germany) according to manufacturer’s instructions. 50 ng of
purified RNA were reverse transcribed in a 20 µl total reaction
mixture with 1.25µM random hexamers, 1× RT-buffer, dNTP
mixture of 1mM each, 1 U/µl RNase inhibitor and 10 U/µl
MuMLV reverse transcriptase (all Biozym). Reaction occurred at
30◦C for 10min, 50◦C for 40min, 99◦C for 5min and subsequent
cooling at 4◦C. The generated cDNA was subjected to gene
specific qPCR using the HotStart DNA Master SYBR Green I
Kit (Biozym) according to the manufacturer’s instructions. The
following gene specific primer sets were used: MACC1 fow:
5′-TTC TTT TGA TTC CTC CGG TGA-3′; MACC1 rev: 5′-
ACT CTG ATG GGC ATG TGC TG-3′; ABCB1 fow: 5′-CCC
ATC ATT GCA ATA GCA GG-3′; ABCB1 rev: 5′-GTT CAA
ACT TCT GCT CCT GA-3′; G6PDH fow: 5′-ATC GAC CAC
TAC CTG GGC AA-3′; G6PDH rev: 5′-TTC TGC ATC ACG
TCC CGG A-3′. Each PCR reaction was performed in a total
volume of 10µl in a LightCycler 480 system (Roche). After initial
denaturation at 95◦C the amplification occurred within 40 cycles
of denaturation (5 s; 95◦C) and a combined primer annealing and
elongation step (45 s; 60◦C). Data analysis was performed with
LightCycler 480 Software release 1.5.0 SP3 (Roche Diagnostics).
Mean values were calculated from duplicates. Each mean value
of the expressed gene was normalized to the respective mean
amount of G6PDH. The results were obtained from three
independent experiments.
Protein Extraction and Western Blotting
300,000 cells were grown in 6-well plates and washed twice with
1x PBS. Cells were lysed with RIPA buffer (50mM Tris-HCl;
pH 7.5, 150mM NaCl, and 1% Nonidet P-40, supplemented
with complete protease inhibitor tablets; Roche Diagnostics)
for 30min on ice. Protein concentration was quantified with
Bicinchoninic Acid Protein Assay Reagent (Thermo Fisher
Scientific), according to the manufacturer’s instructions.
Lysates of equal protein concentration were separated by
SDS-PAGE and transferred to PVDF membranes (Biorad).
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Membranes were blocked for 1 h at room temperature with
5% non-fat dry milk in TBS-T buffer (10mM Tris-HCl; pH
8, 0.1% Tween 20, and 150mM NaCl). Membranes were then
incubated overnight at 4◦C with MACC1 antibody (Sigma-
Aldrich, dilution 1:1,000), ABCB1 antibody (CalBiochem,
dilution 1:1,000) or β-actin antibody (Sigma-Aldrich, dilution
1:10,000), followed by incubation for 1 h at room temperature
with HRP-conjugated anti-rabbit IgG (Promega, dilution
1:10,000) or anti-mouse IgG (Thermo Fisher Scientific,
dilution 1:10,000). Antibody-protein complexes were visualized
with WesternBright ECL HRP substrate (Advansta) and
subsequent exposure to CL-Xposure Films (Thermo Fisher
Scientific). Immunoblotting for β-actin served as the protein
loading control. The results were obtained from three
independent experiments.
Doxorubicin Accumulation Assay
300,000 cells were grown in 6-well plates, were dissociated and
resuspended in 0.3ml DMEM containing 10% FCS. 0.1ml cell
suspension was treated with 30µM doxorubicin for 1 h at 37◦C.
Cells were washed once with PBS and resuspended in DMEM
w/o phenol red (Invitrogen) for another 3 h. Quantification
of intracellular doxorubicin was performed on a LSR II flow
cytometer (BD Biosciences) and analyzed by FlowJo (BD
Biosciences). The results were obtained from three independent
experiments. Geometric means were normalized to time point 0
and the respective parental cell line.
Cell Viability Assay
5,000 cells were plated into 96-well plates and were allowed
to accommodate for 24 h before the treatment started for
48 h. Cell viability was determined with 2 h incubation at a
final concentration of 0.5 mg/ml 3-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich),
solubilizing the formazan crystals formed by metabolic active
cells with DMSO, and measurement of the absorption at
560 nm. The results were obtained from three independent
experiments. After background subtraction (day 0) results
were normalized to their absorption of solvent treated
controls (=100%).
Transfection and ABCB1 Promoter Activity
Assay
The ABCB1 promoter-driven luciferase reporter construct
pMDR1-1202 was a gift from Kathleen Scotto (Addgene plasmid
#37627; http://n2t.net/addgene:37627; RRID: Addgene_37627)
(18). Plasmid transfections were carried out in 6-well
culture plates using TransIT-2020 (Mirus Bio) according to
manufacturer’s instructions. Briefly, 250,000 cells of the cell
lines SW480 and HCT15 were plated per well (three wells
each) and transfected with 2 µg of the pMDR1-1202 reporter
construct. DNA to lipid ratio of 1:3 was used for all the
experiments. Twenty-four hours after transfection, cells were
treated for further 24 h as indicated and luciferase activity
was measured according to manufacturer’s protocol using
the Steady-Glo Luciferase Assay System (Promega) with a
luminometer (Tecan infinite 200 PRO) and normalized to
protein concentration.
Chromatin Immunoprecipitation Assay
(ChIP)
SW480/ev and SW480/MACC1 cells (2 × 106) were plated in
10 cm dishes and grown for 24 h. Cells were cross-linked with
1% formaldehyde, lysed and sonicated to release chromatin. ChIP
assay was performed using the EZ ChIP kit according to the
manufacturer’s instruction (Sigma-Aldrich). The protein-DNA
complexes were precipitated using polyclonal antibodies for RNA
polymerase II (Santa Cruz) and MACC1 (Sigma-Aldrich), or
by immunoglobulin G (Sigma-Aldrich) as negative control. The
extracted DNA was subjected to PCR (28 cycles at 95◦C for 30 s,
60◦C for 30 s, 72◦C for 1min) with two sets of ABCB1 promoter
primers: S2 (−989/−747) forward 5′-AGT GGA AAC ATC CTC
AGA CTA TGC-3′, reverse 5′-CCT GTC CAC TAT TTA CTT
CAA ACT GAG G-3′; and S4 (−619/−363) forward 5′-CGG
GCA TTG ATC TGA CGT CTG AAG TT-3′, reverse 5′-CTC
CGACCTCTCCAATTCTGTATCACCT-3′ (19). ChIP assays
were performed two independent times.
Statistical Analysis
Results are presented as mean ± standard deviation from three
independent experiments. Data normalization and statistical
analysis was performed with the Prism software version 6.01
(GraphPad Software). Significant differences were analyzed using
unpaired Student’s t-test or one-way ANOVA followed by
Bonferroni’s post-hoc test. p < 0.05 was considered to be
statistically significant.
RESULTS
MACC1 Induces ABCB1 Expression in CRC
Cell Lines
Previous analysis of the MACC1-dependent transcriptomic
changes in the CRC cell line SW480, comparing MACC1-
overexpressing SW480/MACC1 cells with their transfection
control SW480/vector, resulted in significant differential
expression of 1382 genes (20). Among the 656 upregulated
genes we found ABCB1 almost 15-fold overexpressed in
SW480/MACC1 cells, indicating a MACC1-dependent ABCB1
expression regulation. We confirmed this result in the same
SW480-derived cell panel with ectopic MACC1 expression. The
almost 40-fold overexpression of MACC1 in SW480/MACC1
cells compared to their control cells SW480 and SW480/ev
(Figure 1A), resulted in a more than 6-fold increase in ABCB1
expression on mRNA levels (p < 0.001; Figure 1B). This
result was confirmed on protein levels of MACC1 and ABCB1
(Figure 1C).
We tested the hypothesis of MACC1 as a regulating factor for
ABCB1 expression by knocking-out MACC1 in the SW620 cell
line, with high endogenous MACC1 expression. The resulting
cell line SW620/ko-MACC1 harbors a homozygous frame shift in
the coding sequence of MACC1, precisely at the binding site for
the gene-specific primer set. The loss of MACC1 in SW620/ko-
MACC1 (Figures 1D,F) reduced the ABCB1 expression on
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FIGURE 1 | ABCB1 expression is modulated by MACC1 in CRC cell lines. (A) Relative expression of MACC1 in SW480 cells, with or without ectopic MACC1
expression. (B) Relative expression of ABCB1 in SW480 cells, with or without ectopic MACC1 expression. (C) Western blot of MACC1, ABCB1, and β-actin in SW480
cells, with or without ectopic MACC1 expression. (D) Relative expression of MACC1 in SW620 cells, with or without MACC1 knock-out. (E) Relative expression of
ABCB1 in SW620 cells, with or without MACC1 knock-out. (F) Western blot of MACC1, ABCB1, and β-actin in SW620 cells, with or without MACC1 knock-out.
Gene expression values were determined by gene specific qRT-PCR, normalized by G6PDH expression, and protein expression levels by Western blotting.
mRNA-level to about 70%, compared to the control cells SW620
and SW620/ctrl (p < 0.05; Figure 1E). Although ABCB1 is very
weakly expressed in parental SW620 cells (21, 22) we were able
to detect a decrease in the protein level of ABCB1 also in the
SW620/ko-MACC1 cells, compared to SW620 and SW620/ctrl
cells (Figure 1F).
MACC1 Expression Decreases Intracellular
Drug Levels and Increases Drug
Resistance
As the expression of ABC transporters in general increases the
efflux of therapeutic drugs, and thus limits treatment efficacy,
we tested the ability of the two CRC cell panels with differential
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FIGURE 2 | MACC1 expression decreases doxorubicin accumulation and increases treatment resistance of CRC cells. (A) Accumulation of doxorubicin in SW480
cells, with or without ectopic MACC1 expression, 3 h after treatment. (B) Cell viability of SW480 cells, with or without ectopic MACC1 expression, after 48 h of
doxorubicin treatment. (C) IC50 values of doxorubicin treatment of SW480 cells, with or without ectopic MACC1 expression. (D) Accumulation of doxorubicin in
SW620 cells, with or without MACC1 knock-out, 3 h after treatment. (E) Cell viability of SW620 cells, with or without MACC1 knock-out, 48 h after doxorubicin
treatment. (F) IC50 values of doxorubicin treatment of SW480 cells, with or without ectopic MACC1 expression. Drug accumulation was determined by flow cytometry.
Cell viability was determined by MTT assays.
MACC1 expression to regulate intracellular accumulation of
doxorubicin. Cells were transiently treated with doxorubicin
and intracellular drug concentration was determined by
flow cytometry (23, 24). Intracellular doxorubicin-derived
fluorescence was decreased by 20% in SW480/MACC1 cells 3 h
after drug exposure, compared to SW480 control cells (p < 0.05,
Figure 2A). Nevertheless, this contributed to an increased drug
resistance in SW480/MACC1 cells. By profiling cell viability after
48 h of doxorubicin treatment with increasing concentrations
(Figure 2B), we observed a nearly doubled IC50 value for
SW480/MACC1 cells of 69.4 nM ± 11.6 (p < 0.05; Figure 2C),
compared to SW480 and SW480/ev cells (28.4 nM ± 5.3 and
33.9 nM± 3.9, respectively).
In contrast, SW620/ko-MACC1 cells retained twice as much
intracellular doxorubicin, compared to SW620 and SW620/ctrl
cells (p < 0.001, Figure 2D), 3 h after doxorubicin treatment.
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In line with this finding, SW620/ko-MACC1 cells became more
susceptible to the cytotoxic effect of doxorubicin (Figure 2E),
compared to SW620 and SW620/ctrl cells. We determined the
IC50 value for SW620 and SW620/ctrl cells with 35.5 nM ± 2.9
and 29.4 nM ± 2.7, respectively, and observed a significantly
decreased IC50 value for SW620/ko-MACC1 cells of 19.3 nM
± 1.4 (p < 0.05; Figure 2F), representing 55 and 65% of the
respective controls.
Lovastatin Decreases the Expression of
MACC1 and ABCB1 in CRC Cells and
Reduces Chemoresistance to Doxorubicin
With the recent identification of statins as transcriptional
inhibitors of MACC1 expression, we aimed at targeting
ABCB1 expression by statin-mediated inhibition of MACC1
transcription.We treated SW480 and SW620 cells with lovastatin
(5 and 30µM, respectively) for 48 h, but also included the
CRC cell line HCT15 (5µM), which has been reported to
endogenously express elevated ABCB1 levels and thus shows
increased multi-drug resistance, but also expresses considerable
amounts of MACC1 (21, 25, 26). As expected by the very
low levels of MACC1 in SW480 cells we did not observe
a significant change in MACC1 expression upon lovastatin
treatment (Figure 3A). But in line with our previous results
(17) we found a reduction of MACC1 expression in lovastatin-
treated SW620 cells to 70% of solvent treatment (p < 0.05;
Figure 3A). Treatment of HCT15 cells resulted in a similar
decrease of MACC1 expression, compared to solvent treated
cells (p < 0.05; Figure 3A). The same pattern in differential
expression of MACC1 upon lovastatin treatment was seen for
ABCB1. SW480 cells showed no significant changes in ABCB1
expression under lovastatin treatment, when compared to solvent
controls (Figure 3B). Interestingly, treatment of SW620 cells
with lovastatin resulted in a significantly lower ABCB1 levels,
compared to solvent treated cells, which was comparable to the
decrease of ABCB1 expression in lovastatin-treated HCT15 cells
(Figure 3B).
Next, HCT15 cells were subjected to combination treatment
with 5µM lovastatin and increasing concentrations of
doxorubicin, determining cell viability after 48 h (Figure 3C). In
line with the reported multi-drug resistance of HCT15 cells, we
determined an IC50 value of 3.61µM ± 0.60 for the treatment
with doxorubicin alone. Additional solvent-treatment resulted
in a similar IC50 value of 3.97µM± 0.39. However, combination
treatment of lovastatin with doxorubicin reduced the IC50 value
to 1.42µM± 0.37 (p < 0.001; Figure 3D), clearly sensitizing the
lovastatin-treated cells to the cytotoxic effect of doxorubicin.
MACC1 Drives ABCB1 Expression at the
Promoter Level
Next, we investigated the potential mechanism of the MACC1-
dependent regulation of ABCB1 expression. First, we confirmed
the induction of ABCB1 transcription with a luciferase-based
reporter assay for the ABCB1 promoter (18). Transfection of
SW480 cells with the reporter construct resulted in rather low
luminescence, which did not significantly change with treatment
of the cells with 5µM lovastatin (Figure 3E). In contrast,
the luciferase activity was more than 4-fold increased when
assayed in HCT15 cells (p < 0.001; Figure 3E). In addition, the
luminescence signal in HCT15 cells was significantly decreased
upon lovastatin treatment (p < 0.05; Figure 3E).
With the focus on the ABCB1 promoter, we performed
chromatin immunoprecipitation experiments in SW480 control
cells, as well as SW480/MACC1 cells, and probing for co-
precipitated regions of the ABCB1 promoter (−989 bp to
−747 bp and −619 bp to −363 bp, respectively) (19). In
general, the occupation of the ABCB1 promoter by RNA
polymerase II (PolII) was lower in SW480 control cells, compared
to SW480/MACC1 cells (Figure 3F) which reflects the initial
ABCB1-mRNA expression data (Figures 1A,B). Pulling down
MACC1 in SW480/MACC1 cells resulted in the co-precipitation
of the ABCB1 promoter, which was neither observed in SW480
control cells nor by pulling down with human immunoglobulin
G (IgG) (Figure 3F).
DISCUSSION
Multi-drug resistance is a major obstacle in the success of
anti-cancer chemotherapy. In the case of CRC, upregulation of
ABC transporters with broad substrate specificity during therapy
critically limits the use of common and effective cytotoxic drugs
like anthracyclines (27). To meet the clinical need to overcome
multi-drug resistance, current research concentrates on small
molecules, either natural or synthetic compounds, which can
functionally inhibit ABC transporters or reduce their induction
under therapy (28–33). In addition, the focus on approved drugs
in overcoming multi-drug resistance allows the fast translation of
novel treatment strategies into the clinics.
In this study, we report the re-sensitization of multi-drug
resistant CRC cells to doxorubicin treatment, by repurposing
lovastatin to interfere with the MACC1-dependent expression
regulation of ABCB1. Initial hints of transcriptional regulation
of ABCB1 by MACC1 were obtained from microarray analyses
comparing MACC1-overexpressing SW480 cells with their
transfection controls, which was independently reported for
generated 5-FU-resistant CRC cell lines (15, 20). We confirmed
the role of MACC1 in modulating ABCB1 expression in
two CRC cell panels with differential MACC1 expression
levels, and found corresponding de- and re-sensitization to
doxorubicin treatment upon ectopic expression or knocking-
out of MACC1, respectively. By luciferase-based reporter
assays and ChIP experiments, we found MACC1 acting on
the promoter of ABCB1, thereby increasing its expression.
Potential regulatory mechanisms of ABCB1 expression contain
constitutive promoter up- or downregulation, as well as
stress/drug induced expression regulation or the improved
survival of chromosomal rearrangements or mutations of the
ABCB1 gene (34). A more distal region of the ABCB1 promoter
shown to increase ABCB1 expression, contains a binding site
for AP-1 and a CCAAT-box, and its transcriptional activity
is regulated by histone acetylation/deacetylation (35). This
region also contains several binding sites for TCF-4/β-catenin
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FIGURE 3 | Lovastatin indirectly increases treatment response to doxorubicin, by reducing the MACC1-dependent ABCB1 expression in MACC1 expressing CRC
cells. (A) Relative expression of MACC1 in SW480, SW620, and HCT15 cells, with or without lovastatin treatment of the indicated concentration. Solvent-treated cells
were used as controls. (B) Relative expression of ABCB1 in SW480, SW620, and HCT15 cells, with or without lovastatin treatment of the indicated concentration.
Solvent-treated cells were used as controls. (C) Cell viability of HCT15 cells, with or without combinatorial treatment of lovastatin and doxorubicin. (D) IC50 values of
doxorubicin treated HCT15 cells, with or without combinatorial treatment of lovastatin. Gene expression was determined by qRT-PCR, and cell viability by MTT
assays. (E) Relative luminescence signals of SW480 and HCT15 cells after transfection with an ABCB1 promoter-driven luciferase-reporter construct, with or without
lovastatin treatment. (F) Chromatin immunoprecipitation of MACC1 in SW480/MACC1 and SW480 control cells and probing for the ABCB1 promoter regions
−989 bp to −747 bp (upper panel) and −619 bp to −363 bp (lower panel). Pulling down RNA polymerase II (PolII) and unspecific human immunoglobulin G (IgG)
served as positive and negative controls, respectively.
transcriptional complexes (36). The presence of MACC1 on
promoters regulating cancer progression and metastasis has
previously been reported (10, 37, 38). But also the impact
of MACC1 expression on β-catenin-dependent target gene
expression was shown for CRC cells (39). Both aspects lead
to the model of activating MACC1-containing protein (sub-)
complexes of TCF-4/β-catenin-driven target gene transcription.
WithABCB1 as such a target gene, the overexpression of MACC1
Frontiers in Oncology | www.frontiersin.org 7 April 2020 | Volume 10 | Article 599
Dahlmann et al. Targeting MACC1 Reverses Multi-Drug Resistance
in cells with activated Wnt/β-catenin signaling leads to increased
resistance to anti-cancer therapies, including anthracyclines
like doxorubicin.
The use of anthracyclines in the treatment of metastasized
and refractory CRC regained attention and is currently evaluated
in a phase II clinical trial (40). But also combination therapy
including doxorubicin has been successfully applied to treat
unresectable colorectal liver metastases (41, 42). The formation
of liver metastases is observed in ∼50% of CRC patients
(43). The expression of MACC1 in CRC correlates with
the occurrence of liver metastases (44) and its role in liver
metastasis has been proven in various animal models (10, 20,
45, 46). Targeting MACC1 expression in CRC cells with the
transcriptional inhibitors rottlerin and lovastatin significantly
reduced metastasis formation to the liver in animal models
(17), and gave rise to the idea to also combat MACC1-
modulated multi-drug resistance in CRC. Lovastatin has
already been reported to increase the effects of anti-cancer
treatment in CRC cells (47, 48) and improves the efficacy of
doxorubicin in animal models of several cancers, including colon
cancer (49, 50).
With the promising results of this study, in overcoming
multi-drug resistance in CRC cells by combination therapy
of lovastatin and doxorubicin, it will be worth to explore
further combination strategies for novel anti-tumor but also
anti-metastatic therapies of CRC in pre-clinical models.
Since both drug classes have proven their efficacy also in
cancer therapy (51, 52), a rapid translation of combination
strategies to combat treatment resistance into the clinics
is feasible.
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